Abstract
Background:
Although it is life-saving, blood transfusion therapy has resulted in risk for transfusion-transmitted infections (TTIs) in the majority of sickle cell anemia being patients.Objectives:
The current study aimed to determine the prevalence of HBV, HCV and different genotypes of HCV among sickle cell anemia (SCA) patients in Ahvaz city, South-western Iran.Materials and Methods:
A cross-sectional study was conducted on 56 SCA patients who referred to the Hemoglobinopathy and Thalassemia research centre during January 2009 to February 2010. Patients` sera were tested for HBsAg and anti-HCV using ELISA and confirmed by PCR (HBV) and RT-PCR (HCV). HCV genotypes were determined with HCV genotype specific primers using HCV genotyping kit.Results:
The overall prevalence rate of HBsAg and anti-HCV were 1.8% (95% CI: 0-5.26) and 12.5% (95% CI: 3.8 - 21.1), respectively. Five of the anti-HCV patients (71.4%) were also HCV RNA positive. The predominant HCV genotype in the patients was 1a (60%), though genotype 1b was found in 40% of the subjects.Conclusions:
It seems that stringent donor selection procedures reduce HCV infection in multi-transfused patients, but there is still serious risk for these patients.Keywords
Hepatitis B Hepatitis C Prevalence Genotype Anemia Sickle Cell
1. Background
Sickle cell anemia (SCA) is one of the most common hereditary hematologic diseases Worldwide. Patients with SCA require multiple blood transfusions and therefore are exposed to transfusion-transmitted infections (TTIs) such as hepatitis B virus (HBV) and particularly hepatitis C virus (HCV). Regular blood or blood products transfusion in patients with sickle cell anemia, thalassemia and haemophilia has improved their overall survival, but carries a definite risk of acquisition of blood-borne virus infections (1-5). Improvement of the people’s knowledge about TTIs risk factors, blood screening strategies, national HBV vaccination program since 1992 for all neonates have led to a dramatic decrease in the prevalence ofTTIs particularly HBV during the last decades (6, 7). However, post transfusion transmission of HCV has still remained a major health concern in multi-transfused patients (1).
Ahvaz city, the capital of Khuzestan province, located in the south-western of Iran, is a tropical area with an approximate population of 1.4 millions (census 2006). Khuzestan has suffered the heaviest damage of all Iranian provinces during a 28-year period including: the Iran-Iraq War (1980-1988), the Gulf War (1990-1991), and the 19-year crisis in Iraq (1990-2009) (8). This geographical location, mass immigration from Iraq, frequent travels to Iraq and neighbouring Arabian countries have all affected prevalence of TTIs in Khuzestan province (9, 10). Moreover, hemoglobinopathies are important health problems throughout Iran particularly in this region (3). The epidemiology of HBV, HCV and different genotypes of HCV among sickle cell anemia (SCA) patients in Ahvaz city has not been extensively investigated, and few data are available on prevalence of the diseases in this area.
2. Objectives
Due to the lack of sufficient reported data from the region, the current study, as the first of its kind in south-western Iran, was conducted to investigate the prevalence of HBV, HCV infections and different genotypes of HCV among SCA patients in Ahvaz.
3. Materials and Methods
3.1. Subjects
This cross-sectional study was performed from January 2009 to February 2010 on SCA patients referring to Research Centre of Thalassemia and Hemoglobinopathies (RCTH) in Ahvaz city, South-western Iran. The study was approved by the institutional review board.
Patients participated in the study after giving written, informed consent (n = 56).Peripheral blood samples were obtained from patients and then serum was separated, aliquoted and stored at -20˚ C. Demographic factors, such as age, duration and number of blood transfusions were obtained from patient records. Furthermore, no patient was receiving interferon therapy or other antiviral drugs.
3.2. Laboratory Assays
All sera were screened using HBsAg and anti-HCV assays with 3-rd generation of immune enzymatic test (ELISA-III). Positive samples were confirmed using DNA polymerase chain reaction (PCR) and nested RT-PCR for HBV and HCV, respectively. All samples were submitted to DNA and RNA extraction, using high pure nucleic acid kits (Roche, Germany) according to the manufacturer’s instructions. HCV RNA was transcribed into cDNA by random primer (Fermentas, Lithuania). The cDNA was targeted using a nested-PCR with specific primers for the conserved sequences in the 5´ non-coding region (5´-NCR) of HCV. HCV genotypes were determined with HCV genotype specific primers using HCV genotype kit (Sacace, Italy).
3.3. Statistical Analysis
Prevalence and 95% confidence intervals (95% CI) were calculated by SPSS software version 13.0 (SPSS Inc., Chicago, IL). Data comparisons were performed using the Chi-square test, Fisher’s exact and two-tailed t-test. The differences were considered significant if P < 0.05.
4. Results
Fifty six SCA patients including 32 (57.1%) males and 24 (42.9%) females were tested. The mean age (± SD) was 22.0 ± 10.62 years (range 2 – 48 years) (Table 1). Seven patients were positive for HCV antibodies, for a prevalence rate of 12.5% (95% CI: 3.8-21.1) (Table 1). One HBsAg-infected patient (1.8%, 95% CI: 0-5.26) was positive for HBV DNA. Furthermore, HCV RNA was detected in 71.4% (5/7) of the anti-HCV-positive patients. The current study found that the prevalence rate of anti-HCV seropositivity was significantly high (P = 0.03) among patients who had started to receive transfusions before 1996 when serological screening for anti-HCV antibody had not been introduced to blood banks in Iran.
HCV Infection Among Sickle Cell Anemia Patients Receiving Multiple Transfusions
| Characteristics | Anti-HCV | HCV RNA | ||||
|---|---|---|---|---|---|---|
| Positive, No. (%) | Negative, No. (%) | Pvalue | Positive, No. (%) | Negative, No. (%) | P value | |
| Prevalence | 7 (12.5) | 49 (87.5) | 5 (8.9) | 51 (91.1) | ||
| Age | 0.07 | 0.05 | ||||
| Mean ± SD | 28.8 ± 10.1 | 21.1 ± 10.4 | 30.0 ± 10.5 | 21.1 ± 10.3 | ||
| Sex | 0.1 | 0.09 | ||||
| Male | 6 (18.8) | 26 (81.2) | 5 (15.6) | 27 (84.4) | ||
| Female | 1 (4.2) | 23 (95.8) | 0 | 24 (100) | ||
| First transfusion | 0.03 | 0.1 | ||||
| Before 1996 | 7 (20.5) | 26 (79.5) | 5 (15.1) | 28 (84.9) | ||
| Starting in 1996 | 0 | 23 (100) | 0 | 23 (100) | ||
| No. of units transfused | 0.008 | 0.04 | ||||
| < 100 | 0 | 21 (100) | 0 | 21 (100) | ||
| 100-200 | 0 | 12 (100) | 0 | 12 (100) | ||
| > 200 | 7 (30.4) | 16 (69.6) | 5 (21.7) | 18 (78.2) | ||
The prevalence of anti-HCV and HCV RNA was significantly higher in patients who received blood transfusion more than 200 times compared to subjects with blood transfusion less than 100 times (P = 0.008 and P = 0.04, respectively). No statistically significant difference was observed between anti-HCV or HCV RNA positive and negative patients with respect to age or sex. In the end, predominant HCV genotype among sickle cell anemia patients in theregion was 1a (3/5, 60%), whilst genotype 1b was found in 40% (2/5) of the patients.
5. Discussion
Due to the large number of blood transfusions received, sickle cell anemia patients are at high risk for acquiring HCV and HBV infections. Prevalence of hepatitis infection in these patients is reported by several authors ranging between 4.5 to 21% for HCV (2, 11-13) and 3 to 39% for HBV (14-16). The current study found that the prevalence rates of anti-HCV and HBsAg were 12.5% (7/56) and 1.8% (1/56), respectively. Since serologic tests became available, the blood donors screening has been performed in most countries. In Iran, mandatory anti-HCV screening was introduced to blood banks in 1996 (1, 5, 9). The current study results showed that 58.9% of SCA patients had been transfused for more than 12 years. It was suggested that the patient who received blood products could be exposed at higher risk to HCV.
In the current study the frequency of anti-HCV positive among patients with blood transfusion was significant (P = 0.008). Recent studies of SCA patients show that the prevalence of anti-HCV varied (4.5 to 21%) (2, 11-13), which suggests that the geographical area may affect the potential risk of HCV in patients (17-19). Moreover, one of the most common causes of HCV transmission by transfusion is the occurrence of new infections in blood donors. Hajiani et al. reported that blood transfusion is the leading risk factor for HCV acquisition in Khuzestan province as 52% of HCV-positive individuals were diagnosed with chronic haemolytic anemia and received regular blood transfusion (19).
Prevalence of HCV in blood donors in different provinces of Iran has been reported to be 0.3–0.97% (1, 5, 19, 20). Nevertheless, a recent study on 2376 blood donors in Ahvaz, showed that 2.3% of the subjects were positive for anti-HCV (21).
It is noteworthy to mention that the most important problem with the studies is the possibility of selection bias and low positive analytical value of anti-HCV detection by ELISA (1, 22). However, in the current study anti-HCV positivity was detected in 7 (12.5%) of the 56 SCA patients. This rate is higher than that of the blood donors in the region. Furthermore, the anti-HCV prevalence in the current study (12.5%) was lower than that ofthe multi-transfused patients in some neighbouring Arabic countries (29.4 to 44%) (23-25) and other countries such as Pakistan (48.6%) (26) and Brazil (14.1%) (13).
However, in the previous studies the male preponderance in HCV-infected patients was reported (19, 20 ). The results of the present study were consistent with the previous studies though they were not statistically significant (Table 1). HCV RNA was detected in 71.4% of the anti-HCV-positive patients. In different studies, this rate was a wide range between 48-82% (13 , 21 , 27). Although the use of 3-rd generation of enzyme immunoassays (EIAs) is often appropriate and practical, particularly in routine HCV diagnosis, more care should be taken about ELISA test limitations to avoid unnecessary distress to patients, as a result of false-positive HCV-antibody detection. Studies of some neighbouring Arabic countries reported an HCV infection rate of 29.4 -44% among multi-transfused patients (23 - 25).Khuzestan province shares a land, river and sea border with these countries. In addition, the Iran-Iraq War of 1980-1988, has had a devastating impact on public health. Moreover, during a period of 18 years, due to poor security and living conditions, many Iraqi refugees have crossed over the Iraqi border to Iran, mainly to the south western regions ( 8 , 10 ). The geographical situation, mass immigration from Iraq, where a significantly higher prevalence of anti-HCV has been found among different populations (28, 29) and frequent travels between Khuzestan province and neighbouring Arabic countries, all could affect prevalence of TTIs in the region.
In the current study, HBsAg positivity and HBV DNA was found at the rate of 1.8% among the SCA patients which was less than those of the blood donors in Iran (1.8% vs. 3%) (6). This could be due to vaccination against HBV for newborn and particularly high-risk groups since 1992 and the compulsory screening of donated bloods by the local blood banks since 1995 (6, 7). There is no previous study regarding the frequency of HBsAg in SCA patients in the region. However, it seems that the rate of HBV infection in multi-transfused patients has been declining in Iran since 1995 (17).
To our best knowledge, the current study was the first report on prevalence of HCV genotypes among SCA patients in Iran. Two HCV genotypes were identified in these patients in Ahvaz city: subtypes 1a and 1b. Subtype 1a was predominant (60%) similar to the recent studies in different populations in the region (18, 21). This finding is different from HCV genotypes distribution and the high frequency of genotype HCV 1a/1b plus HCV 4 and HCV 2/2a plus HCV 4in multi-transfused patients living in neighbouring countries, such as Bahrain and Saudi Arabia respectively, sharing sea boarder with Khuzestan province (4).
In conclusion, the current study provided information that will assist in developing intervention guidelines to reduce the risk of acquiring TTIs, which continue to be a significant public health problem in Khuzestan province. The prevalence of HCV infection decreased after introduction of screening tests and stringent donor selection procedures, but TTIs in patients with SCA is still serious risk for these patients.
Acknowledgements
References
-
1.
Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med. 2005;8(2):84-90.
-
2.
Beltran M, Navas MC, De la Hoz F, Mercedes Munoz M, Jaramillo S, Estrada C, et al. Hepatitis C virus seroprevalence in multi-transfused patients in Colombia. J Clin Virol. 2005;34 Suppl 2:S33-8. [PubMed ID: 16461238].
-
3.
Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, Yektaparast B, Zahedi MJ, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med. 2006;9(4):319-23. [PubMed ID: 17061602].
-
4.
Qadi AA, Tamim H, Ameen G, Bu-Ali A, Al-Arrayed S, Fawaz NA, et al. Hepatitis B and hepatitis C virus prevalence among dialysis patients in Bahrain and Saudi Arabia: a survey by serologic and molecular methods. Am J Infect Control. 2004;32(8):493-5. [PubMed ID: 15573057]. https://doi.org/10.1016/S0196655304003669.
-
5.
Rezvan H, Abolghassemi H, Kafiabad SA. Transfusion-transmitted infections among multitransfused patients in Iran: a review. Transfus Med. 2007;17(6):425-33. [PubMed ID: 18067646]. https://doi.org/10.1111/j.1365-3148.2007.00794.x.
-
6.
Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):403-6. [PubMed ID: 18193122].
-
7.
Merat S, Rezvan H, Nouraie M, Jamali A, Assari S, Abolghasemi H, et al. The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: a population-based study. Arch Iran Med. 2009;12(3):225-31. [PubMed ID: 19400598].
-
8.
Assarehzadegan MA, Shakerinejad G, Amini A, Rezaee SA. Seroprevalence of hepatitis E virus in blood donors in Khuzestan Province, southwest Iran. Int J Infect Dis. 2008;12(4):387-90. [PubMed ID: 18063401]. https://doi.org/10.1016/j.ijid.2007.09.015.
-
9.
Assarehzadegan MA, Shakerinejad G, Noroozkohnejad R, Amini A, Rahim Rezaee SA. Prevalence of hepatitis C and B infection and HC V genotypes among hemodialysis patients in Khuzestan province, southwest Iran. Saudi J Kidney Dis Transpl. 2009;20(4):681-4. [PubMed ID: 19587521].
-
10.
Boroujerdnia Ghafourian M, Zadegan MA, Zandian Khoda Morad, Rodan Morteza Haghirizadeh. Prevalence of hepatitis-C virus (HCV) among thalassemia patients in Khuzestan Province, Southwest Iran. Pak J Med Sci Q. 2009;25:113-7.
-
11.
DeVault KR, Friedman LS, Westerberg S, Martin P, Hosein B, Ballas SK. Hepatitis C in sickle cell anemia. J Clin Gastroenterol. 1994;18(3):206-9. [PubMed ID: 8034915].
-
12.
Ocak S, Kaya H, Cetin M, Gali E, Ozturk M. Seroprevalence of hepatitis B and hepatitis C in patients with thalassemia and sickle cell anemia in a long-term follow-up. Arch Med Res. 2006;37(7):895-8. [PubMed ID: 16971232]. https://doi.org/10.1016/j.arcmed.2006.04.007.
-
13.
Torres MC, Pereira LM, Ximenes RA, Araujo AS, Secaf M, Rodrigues SS, et al. Hepatitis C virus infection in a Brazilian population with sickle-cell anemia. Braz J Med Biol Res. 2003;36(3):323-9. [PubMed ID: 12640496].
-
14.
Abiodun PO, Fatunde OJ, Flach KH, Buck T. Increased incidence of hepatitis B markers in children with sickle-cell anemia. Blut. 1989;58(3):147-50. [PubMed ID: 2930857].
-
15.
Angyo IA, Yakubu AM. Lack of association between some risk factors and hepatitis B surface antigenaemia in children with sickle cell anaemia. West Afr J Med. 2001;20(3):214-8. [PubMed ID: 11922153].
-
16.
Soliman AT, Bassiouny MR, Elbanna NA. Study of hepatic functions and prevalence of hepatitis-B surface antigenaemia in Omani children with sickle cell disease. J Trop Pediatr. 1995;41(3):174-6. [PubMed ID: 7636938].
-
17.
Alavian SM, Bagheri-Lankarani K, Mahdavi-Mazdeh M, Nourozi S. Hepatitis B and C in dialysis units in Iran: changing the epidemiology. Hemodial Int. 2008;12(3):378-82. [PubMed ID: 18638096]. https://doi.org/10.1111/j.1542-4758.2008.00284.x.
-
18.
Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology (Carlton). 2003;8(5):256-60. [PubMed ID: 15012714].
-
19.
Hajiani E, Hashemi J, Masjedizadeh R, Shayesteh AA, Idani E, Rajabi T. Seroepidemiology of hepatitis C and its risk factors in Khuzestan Province, south-west of Iran: a case-control study. World J Gastroenterol. 2006;12(30):4884-7. [PubMed ID: 16937474].
-
20.
Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: a case-control study. J Gastroenterol Hepatol. 2002;17(10):1092-7. [PubMed ID: 12201870].
-
21.
Farshadpour F, Makvandi M, Samarbafzadeh AR, Jalalifar MA. Determination of hepatitis C virus genotypes among blood donors in Ahvaz, Iran. Indian J Med Microbiol. 2010;28(1):54-6. [PubMed ID: 20061766]. https://doi.org/10.4103/0255-0857.58731.
-
22.
Singh H, Pradhan M, Singh RL, Phadke S, Naik SR, Aggarwal R, et al. High frequency of hepatitis B virus infection in patients with beta-thalassemia receiving multiple transfusions. Vox Sang. 2003;84(4):292-9. [PubMed ID: 12757503].
-
23.
al-Mahroos FT, Ebrahim A. Prevalence of hepatitis B, hepatitis C and human immune deficiency virus markers among patients with hereditary haemolytic anaemias. Ann Trop Paediatr. 1995;15(2):121-8. [PubMed ID: 7677412].
-
24.
Rikabi A, Bener A, Al-Marri A, Al-Thani S. Hepatitis B and C viral infections in chronic liver disease: a population based study in Qatar. East Mediterr Health J. 2009;15(4):778-84. [PubMed ID: 20187528].
-
25.
Saxena AK, Panhotra BR, Naguib M, Aboras MN, Sundaram DS, Venkateshappa CK, et al. Prevalence of hepatitis C antibodies among hemodialysis patients in Al-hasa region of saudi arabia. Saudi J Kidney Dis Transpl. 2001;12(4):562-5. [PubMed ID: 18209404].
-
26.
Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. World J Gastroenterol. 2009;15(45):5647-53. [PubMed ID: 19960560].
-
27.
Broumand B, Shamshirsaz AA, Kamgar M, Hashemi R, Aiazi F, Bekheirnia M, et al. Prevalence of hepatitis C infection and its risk factors in hemodialysis patients in tehran: preliminary report from "the effect of dialysis unit isolation on the incidence of hepatitis C in dialysis patients" project. Saudi J Kidney Dis Transpl. 2002;13(4):467-72. [PubMed ID: 17660669].
-
28.
Al-Kubaisy WA, Al-Naib KT, Habib M. Seroprevalence of hepatitis C virus specific antibodies among Iraqi children with thalassaemia. East Mediterr Health J. 2006;12(1-2):204-10. [PubMed ID: 17037239].
-
29.
Al-Kubaisy WA, Al-Naib KT, Habib MA. Prevalence of HCV/HIV co-infection among haemophilia patients in Baghdad. East Mediterr Health J. 2006;12(3-4):264-9. [PubMed ID: 17037693].